INSMED INC (INSM) Fundamental Analysis & Valuation
NASDAQ:INSM • US4576693075
Current stock price
139.5 USD
-0.02 (-0.01%)
At close:
139.5 USD
0 (0%)
After Hours:
This INSM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. INSM Profitability Analysis
1.1 Basic Checks
- INSM had negative earnings in the past year.
- In the past year INSM has reported a negative cash flow from operations.
- In the past 5 years INSM always reported negative net income.
- INSM had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -56.38%, INSM perfoms like the industry average, outperforming 43.93% of the companies in the same industry.
- INSM's Return On Equity of -172.78% is on the low side compared to the rest of the industry. INSM is outperformed by 66.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -56.38% | ||
| ROE | -172.78% | ||
| ROIC | N/A |
ROA(3y)-52.62%
ROA(5y)-44.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Gross Margin value of 79.73%, INSM belongs to the best of the industry, outperforming 84.59% of the companies in the same industry.
- In the last couple of years the Gross Margin of INSM has remained more or less at the same level.
- INSM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.73% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5Y1.03%
2. INSM Health Analysis
2.1 Basic Checks
- INSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
- INSM has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for INSM has been increased compared to 5 years ago.
- The debt/assets ratio for INSM has been reduced compared to a year ago.
2.2 Solvency
- INSM has an Altman-Z score of 7.86. This indicates that INSM is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of INSM (7.86) is better than 79.19% of its industry peers.
- INSM has a Debt/Equity ratio of 0.98. This is a neutral value indicating INSM is somewhat dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.98, INSM is doing worse than 75.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.98 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.86 |
ROIC/WACCN/A
WACC8.77%
2.3 Liquidity
- INSM has a Current Ratio of 3.83. This indicates that INSM is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 3.83, INSM is in line with its industry, outperforming 45.09% of the companies in the same industry.
- INSM has a Quick Ratio of 3.54. This indicates that INSM is financially healthy and has no problem in meeting its short term obligations.
- INSM's Quick ratio of 3.54 is in line compared to the rest of the industry. INSM outperforms 43.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.83 | ||
| Quick Ratio | 3.54 |
3. INSM Growth Analysis
3.1 Past
- The earnings per share for INSM have decreased strongly by -14.67% in the last year.
- Looking at the last year, INSM shows a very strong growth in Revenue. The Revenue has grown by 66.73%.
- Measured over the past years, INSM shows a very strong growth in Revenue. The Revenue has been growing by 29.83% on average per year.
EPS 1Y (TTM)-14.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)66.73%
Revenue growth 3Y35.2%
Revenue growth 5Y29.83%
Sales Q2Q%152.62%
3.2 Future
- Based on estimates for the next years, INSM will show a very strong growth in Earnings Per Share. The EPS will grow by 29.72% on average per year.
- The Revenue is expected to grow by 66.02% on average over the next years. This is a very strong growth
EPS Next Y54.28%
EPS Next 2Y44.06%
EPS Next 3Y37.98%
EPS Next 5Y29.72%
Revenue Next Year210.82%
Revenue Next 2Y127.13%
Revenue Next 3Y95.62%
Revenue Next 5Y66.02%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. INSM Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for INSM. In the last year negative earnings were reported.
- Also next year INSM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as INSM's earnings are expected to grow with 37.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.06%
EPS Next 3Y37.98%
5. INSM Dividend Analysis
5.1 Amount
- No dividends for INSM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
INSM Fundamentals: All Metrics, Ratios and Statistics
139.5
-0.02 (-0.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-09 2026-01-09/dmh
Earnings (Next)05-06 2026-05-06
Inst Owners101.55%
Inst Owner Change-1.17%
Ins Owners0.54%
Ins Owner Change-10.31%
Market Cap30.07B
Revenue(TTM)606.42M
Net Income(TTM)-1.28B
Analysts85.38
Price Target216.28 (55.04%)
Short Float %5.45%
Short Ratio3.76
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-22.54%
Min EPS beat(2)-28.09%
Max EPS beat(2)-16.99%
EPS beat(4)0
Avg EPS beat(4)-19.6%
Min EPS beat(4)-28.87%
Max EPS beat(4)-4.46%
EPS beat(8)1
Avg EPS beat(8)-15.82%
EPS beat(12)2
Avg EPS beat(12)-15.8%
EPS beat(16)4
Avg EPS beat(16)-12.57%
Revenue beat(2)2
Avg Revenue beat(2)35.81%
Min Revenue beat(2)20.71%
Max Revenue beat(2)50.91%
Revenue beat(4)3
Avg Revenue beat(4)17.97%
Min Revenue beat(4)-1.17%
Max Revenue beat(4)50.91%
Revenue beat(8)4
Avg Revenue beat(8)8.23%
Revenue beat(12)5
Avg Revenue beat(12)5.82%
Revenue beat(16)6
Avg Revenue beat(16)4.28%
PT rev (1m)-1.33%
PT rev (3m)-0.48%
EPS NQ rev (1m)1.63%
EPS NQ rev (3m)20.02%
EPS NY rev (1m)4.12%
EPS NY rev (3m)21.45%
Revenue NQ rev (1m)20.52%
Revenue NQ rev (3m)58.75%
Revenue NY rev (1m)17.63%
Revenue NY rev (3m)37.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 49.58 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 40.69 | ||
| P/tB | 59.52 | ||
| EV/EBITDA | N/A |
EPS(TTM)-6.41
EYN/A
EPS(NY)-2.93
Fwd EYN/A
FCF(TTM)-4.49
FCFYN/A
OCF(TTM)-4.34
OCFYN/A
SpS2.81
BVpS3.43
TBVpS2.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -56.38% | ||
| ROE | -172.78% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.73% | ||
| FCFM | N/A |
ROA(3y)-52.62%
ROA(5y)-44.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5Y1.03%
F-Score4
Asset Turnover0.27
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.98 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 169.93% | ||
| Cap/Sales | 5.37% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.83 | ||
| Quick Ratio | 3.54 | ||
| Altman-Z | 7.86 |
F-Score4
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)143.21%
Cap/Depr(5y)111.56%
Cap/Sales(3y)5.25%
Cap/Sales(5y)4.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y54.28%
EPS Next 2Y44.06%
EPS Next 3Y37.98%
EPS Next 5Y29.72%
Revenue 1Y (TTM)66.73%
Revenue growth 3Y35.2%
Revenue growth 5Y29.83%
Sales Q2Q%152.62%
Revenue Next Year210.82%
Revenue Next 2Y127.13%
Revenue Next 3Y95.62%
Revenue Next 5Y66.02%
EBIT growth 1Y-26.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.95%
EBIT Next 3Y38.19%
EBIT Next 5YN/A
FCF growth 1Y-37.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-36.72%
OCF growth 3YN/A
OCF growth 5YN/A
INSMED INC / INSM Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for INSMED INC?
ChartMill assigns a fundamental rating of 3 / 10 to INSM.
Can you provide the valuation status for INSMED INC?
ChartMill assigns a valuation rating of 1 / 10 to INSMED INC (INSM). This can be considered as Overvalued.
How profitable is INSMED INC (INSM) stock?
INSMED INC (INSM) has a profitability rating of 1 / 10.
What is the financial health of INSMED INC (INSM) stock?
The financial health rating of INSMED INC (INSM) is 4 / 10.